secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-04-11T23:59:59+00:00
Accession:  0001104659-24-046096
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign
--------------------------------------------------------------------------------

- Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.
- Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.
- Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.
- New directors are independent under Nasdaq standards and will receive standard non-employee director compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/0001104659-24-046096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000110465924046096/tm2411574d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer